Table 3 Comparison of proliferation and IC50 values (µM) of temozolomide (TMZ) treatment (48 h exposition) in primary glioblastoma cells isolated from patient´s samples (GBM26, GBM43 and GBM59). Endpoint detection was performed using WST-1 analysis
From: Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients
glioblastoma cells | proliferation [%] | TMZ [µM] |
|---|---|---|
GBMLe3 | 100.00 ± 3.06 | 2941.00 |
GBMLe4 | 514.98 ± 10.09 | 529.60 |
GBMDo2 | 230.58 ± 7.00 | 35435.00 |